Benefits of Novel Oral Anticoagulant Agents for Thromboprophylaxis after Total Hip or Knee Arthroplasty
Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are among the most common orthopedic procedures performed in the United States, with almost 300,000 THA surgeries and more than 500,000 TKA surgeries performed annually.1 This number is projected to rise to approximately 572,000 annual THA surgeries and 3.5 million annual TKA surgeries by 2030.1 THA and TKA procedures improve mobility and quality of life, but patients undergoing these surgeries are at a significantly increased risk for developing postoperative venous thromboembolism (VTE).2-4 VTE
A Paradigm Shift in Anticoagulation?
R. Amy Puenpatom, PhD, Sheryl L. Szeinbach, PhD, RPh, Larry Ma, PhD, Rami H. Ben-Joseph, PhD, Kent H. Summers, PhD, BSPharm
Chronic pain is experienced by more than one third of the US population.1 Regardless of disease etiology or individual characteristics, chronic pain is debilitating and has a profound impact on emotional and physical functioning.2,3 For chronic pain, which is characterized as pain lasting 3 or more months,4 opioid analgesics are considered part of a multifaceted strategy to manage moderate-to-severe pain for a number of conditions involving the musculoskeletal system (eg, osteoarthritis, low back pain), neurologic system (eg, diabetic neuropathy, spinal cord
Daily Average Consumption of 2 Long-Acting Opioids and Coverage Decisions
Brett Pinsky, MPH, James Harnett, PharmD, Ryne Paulose-Ram, PhD, Jack Mardekian, PhD, Navendu Samant, PhD, Kavita V. Nair, PhD
Health plans are increasingly offering payment incentives to motivate providers to strive for improving the quality of patient care based on established criteria such as those set forth by the National Committee for Quality Assurance (NCQA).1,2
What Certification Really Means for Physician Quality
The Hickory Project: Controlling Healthcare Costs and Improving Outcomes for Diabetes Using the Asheville Project Model
Barry A. Bunting, PharmD, DSNAP, Grover Lee, PharmD, BCMCM, Grant Knowles, PharmD, Christine Lee, PharmD, BCPS, CLS, Paul Allen, PhD, MBA
This follow-up study was conducted to determine if a previously successful, community-based, chronic disease management model, known as the Asheville Project, could be replicated in other communities in the country.
Keeping a Lid on Health Plan Costs, One Patient at a Time
Robert Lee Page ii, PharmD, MSPH, FAHA, FCCP, FASCcP, FASHP, BCPS, Vahram Ghushchyan, PhD, Kavita Nair, PhD, James T. Kenney, RPh, MBA
Despite advances in life-saving medical interventions and pharmacotherapies, cardiovascular disease (CVD) continues to be a leading killer in the United States.1 The spectrum of CVD consists of hypertension, chronic heart disease (CHD; including myocardial infarction [MI] and angina), heart failure, and stroke.
Prevention Efforts before Disease Strikes the Key to a Healthy Population of Young Adults
Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications
Karmella T. Thomas, BS, RD, Katie B. Lyons, MS II, Loida D. Nguyen, PharmD, BCPS, Raymond A. Plodkowski, MD, Quang T. Nguyen, DO, FACP, FACE, FTOS
Diabetes is the leading cause of kidney failure, nontraumatic lower-limb amputations, and new cases of blindness among adults in the United States.
New Therapies with Novel Mechanisms of Action Are Urgently Needed for Type 2 Diabetes
The prevalence of diabetes has increased dramatically in recent decades. This trend highlights the importance of prevention and appropriate therapy to reduce cardiovascular events in patients with diabetes. Reaching adequate blood glucose control is important in decreasing microvascular complications associated with diabetes; however, good lipid management is vital for reducing the incidence of cardiovascular events in patients with diabetes.1-4
The Time Is Now to Promote Aggressive Lipid Management to Prevent Macrovascular Complications in Patients with Type 2 Diabetes
The Janus kinase (JAK) 1/2 inhibitor ruxolitinib dramatically improves response rates in treating 3 forms of myelofibrosis, according to results from 2 randomized phase 3 clinical trials, known as COMFORT (Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment) I and II.
In both COMFORT trials, ruxolitinib was significantly superior to the best available therapy in reducing spleen size and symptom burden and improving quality of life. The studies are the first randomized trials of drug therapy for myelofibrosis.
A new regimen of oral busulfan (Myleran) and melphalan (Alkeran) extended event-free survival over a regimen of carboplatin (Paraplatin), etoposide (Eposin), and melphalan (CEM) in a phase 3 clinical trial of patients with high-risk pediatric neuroblastoma.
The trial was terminated early once the superiority of the busulfan-melphalan myeloablative regimen became evident, said lead investigator Ruth Ladenstein, MD, Associate Professor of Pediatrics, University of Vienna, and St Anna Children’s Cancer Research Institute, Vienna.
Page 9 of 12
Results 81 - 90 of 120
Results 81 - 90 of 120